Organigram Global Inc. (DE:0OG)
NASDAQ:0OG
0OG Stock Chart & Stats
€1.25
--
Market closed
€1.25
--
Day’s Range― - ―
52-Week Range€0.81 - €1.82
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.00
Market Cap
€123.24M
Enterprise Value€145.31M
Total Cash (Recent Filing)€54.75M
Total Debt (Recent Filing)€8.20M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Jul 09, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding136,468,690
10 Day Avg. Volume29
30 Day Avg. Volume30
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.03
Price to Sales (P/S)1.39
P/FCF Ratio-14.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.01Price Target Upside61.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.08
Revenue Forecast (FY)€212.89M
Bulls Say, Bears Say
Bulls Say
Acquisition And European ExpansionAnalyst considers the acquisition strategically significant as it positions Organigram in Germany and creates a platform to expand across European markets, supporting potential revenue growth.
Higher-margin Product SalesAnalyst notes the deal enables Organigram to sell higher-margin flower into European markets, which could improve overall profitability as international sales scale.
Operational Strength And DistributionAnalyst points to Sanity Group's improving gross margins and positive operating profitability, together with the Motif acquisition's added sales channels, as elements that can strengthen margins and accelerate top-line growth.
Bears Say
Balance Sheet Impact And Shareholder DilutionAnalyst warns the transaction requires cash and issuance of Organigram shares, which could weaken the balance sheet and alter shareholder structure through dilution.
Operational Disruption And Product Quality RiskAnalyst highlights operational disruptions and product quality issues that constrained international shipments and increased competitive pressure in certain categories, posing execution risk.
Revenue And Earnings ShortfallAnalyst reports net revenue missed expectations because international sales were weaker and domestic adult-use demand softened, resulting in adjusted operating earnings falling short of forecasts.
Organigram Global News
0OG FAQ
What was Organigram Global Inc.’s price range in the past 12 months?
Organigram Global Inc. lowest stock price was €0.81 and its highest was €1.82 in the past 12 months.
What is Organigram Global Inc.’s market cap?
Organigram Global Inc.’s market cap is €123.24M.
When is Organigram Global Inc.’s upcoming earnings report date?
Organigram Global Inc.’s upcoming earnings report date is Jul 09, 2026 which is in 11 days.
How were Organigram Global Inc.’s earnings last quarter?
Organigram Global Inc. released its earnings results on May 12, 2026. The company reported -€0.006 earnings per share for the quarter, beating the consensus estimate of -€0.007 by <€0.001.
Is Organigram Global Inc. overvalued?
According to Wall Street analysts Organigram Global Inc.’s price is currently Undervalued.
Does Organigram Global Inc. pay dividends?
Organigram Global Inc. does not currently pay dividends.
What is Organigram Global Inc.’s EPS estimate?
Organigram Global Inc.’s EPS estimate is >-0.01.
How many shares outstanding does Organigram Global Inc. have?
Organigram Global Inc. has 136,468,690 shares outstanding.
What happened to Organigram Global Inc.’s price movement after its last earnings report?
Organigram Global Inc. reported an EPS of -€0.006 in its last earnings report, beating expectations of -€0.007. Following the earnings report the stock price went up 4.798%.
Which hedge fund is a major shareholder of Organigram Global Inc.?
Currently, no hedge funds are holding shares in DE:0OG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organigram Global Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€2.01 (61.17% Upside)
€2.01 (61.17% Upside)
Blogger Sentiment
Bullish
DE:0OG Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €69.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.42%
12-Months-Change
Fundamentals
Return on Equity
-6.83%
Trailing 12-Months
Asset Growth
-0.05%
Trailing 12-Months
Company Description
Organigram Global Inc.
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.
0OG Company Deck
0OG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and financial progress: strong year-over-year revenue (+49%), adjusted gross profit (+67%), adjusted EBITDA (+273%), cultivation scale gains (+43% harvested kg), and important plant-science and manufacturing advances. Management emphasized recovery from discrete disruptions (BC strike, out-of-spec international flower) and reiterated full-year guidance (> $300M revenue) and confidence in margin expansion. Key risks include a roughly $3.5M international revenue impact from out-of-spec flower (now being repurposed domestically), elevated competition in vapes/IPRs, near-term working capital-driven cash usage, pending EU GMP timing, and slow U.S. penetration. Overall, the positive financial momentum, margin improvement, operational breakthroughs and clear mitigation plans outweigh the temporary operational and market headwinds.View all DE:0OG earnings summaries0OG Stock 12 Month Forecast
Average Price Target
€2.01
▲(61.17% Upside)
Technical Analysis
Canopy Growth
―
Aurora Cannabis
―
Cronos Group
―
Curaleaf Holdings
―
Green Thumb Industries
―
Options Prices
Currently, No data available
---